Abbott Says Amulet Superior To Boston Scientific's Watchman In Stroke Study

Abbott Laboratories ABT has announced late-breaking data from the Amulet LAA Occluder IDE trial.
The head-to-head study compared Abbott's Amplatzer Amulet Left Atrial Appendage (LAA) Occluder with Boston Scientific Corporation's BSX Watchman device for atrial fibrillation at an increased risk of stroke.
Results from the study demonstrated that Abbott's Amulet Occluder was successfully implanted in 98.4% of patients compared to 96.4% of patients receiving the Watchman device. Its demonstrated superiority for the primary endpoint of LAA closure compared to Watchman, 98.9% versus 96.8%.
Amulet Occluder was non-inferior to the comparator device for the co-primary safety endpoint and co-primary effectiveness endpoints. Also, Amulet did not require the use of blood thinners for participants following implant in the study.
Watchman patients were mostly (82%) discharged on anticoagulant therapy (warfarin plus aspirin).
In contrast, only 20% of Amulet patients were discharged on anticoagulants, and most (75.7%) were released on dual antiplatelet therapy (clopidogrel plus aspirin).
Price Action: ABT shares are up 1.14% at $125.99, and BSX stock is up 0.08% at $44.84 during the market session on the last check Monday.